Inactive Instrument

Company BioDelivery Sciences International, Inc.

Equities

BDSI

US09060J1060

Pharmaceuticals

Business Summary

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Company builts a portfolio of products that includes utilizing its BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's product candidates include BELBUCA (buprenorphine buccal film), CIII, for chronic pain; Symproic (naldemedine), for opioid induced constipation; ELYXYB (celecoxib oral solution) for acute treatment of migraine, and ONSOLIS (fentanyl buccal soluble film) for breakthrough cancer pain.

Number of employees: 200

Managers

Managers TitleAgeSince
Chief Executive Officer 53 22-03-21
Director of Finance/CFO 48 22-03-21
General Counsel 40 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 443 0 0 91.41 %
Stock B 1 106,494,480 97,342,470 ( 91.41 %) 3,265,684 ( 3.067 %)

Company contact information

BioDelivery Sciences International, Inc.

100 Technology Center Drive Suite 300

02072, Stoughton

+919 582 9050

http://www.bdsi.com
address BioDelivery Sciences International, Inc.(BDSI)
  1. Stock Market
  2. Equities
  3. BDSI Stock
  4. Company BioDelivery Sciences International, Inc.